DB
ATYR

Dmitry Balyasny’s aTyr Pharma ATYR Stock Holding History

Dmitry Balyasny’s Portfolio ATYR Stock Details ATYR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-100,000
Closed -$72.1K – 3644
2025
Q3 		$72.1K Buy
+100,000
New +$453K ﹤0.01% 2807

Other funds holding ATYR

Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $69.6B AUM 42.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $174M AUM
Jane Street
Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Dmitry Balyasny's ATYR Position: Q2 2026 in Review

Dmitry Balyasny increased its aTyr Pharma (ATYR) stake by 123% in Q2 2026, buying an estimated $8.29K and bringing the position to 23,015 shares worth $13.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2933.

Dmitry Balyasny first reported a position in ATYR in Q4 2024 and has held it in 4 quarters since. The position peaked at $686K in Q1 2025. 90 funds tracked by Wall St. Rank hold ATYR as of Q2 2026.

  • Dmitry Balyasny held 23,015 shares of aTyr Pharma worth $13.7K as of Q2 2026.
  • Dmitry Balyasny bought 12,685 aTyr Pharma shares in Q2 2026, an estimated $8.29K.
  • aTyr Pharma made up ﹤0.01% of Dmitry Balyasny's portfolio in Q2 2026, its #2933 holding.
  • Dmitry Balyasny first reported a position in aTyr Pharma in Q4 2024 and has held it in 4 quarters since.
  • Dmitry Balyasny's aTyr Pharma position peaked at $686K in Q1 2025.
  • 90 funds tracked by Wall St. Rank held aTyr Pharma as of Q2 2026.

Based on Balyasny Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.